Ott: Illumina effectively holds a justified monopoly in DNA sequencing hardware
Gabriel Ott · a16z Podcast | On the Genomics of Disease, From Science to Business · Jan 2, 2019 · at 16:38
Gabriel Ott discusses DNA sequencing market dynamics and Illumina's hardware dominance on the a16z Podcast.
0:00 / 0:06exact quote · 6.9s
▶ Watch the full episode on YouTube → 720p mp4 · rendered on demand · StarZero watermark
“Illumina effectively is a monopoly in the space of DNA sequencing, and in a lot of ways, rightly so.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Gabriel Ott
Otte: Insurance payers and clinicians are blocking diagnostic innovation
“It's really the payers and some of the clinicians that are being the inhibitors to this progress.”
Ott: Dynamic DNA testing will enable detection of any disease with immune changes
“The underlying biology should theoretically enable us to detect any diseases where there is an immune change.”
Ott: Mammography Screenings Have a 50% False Positive Rate
“Breast cancer, and specifically mammography as a screening method, has a false positive rate of 50%.”
Otte: PSA tests and mammograms have false positive rates up to 75%
“In the field of cancer screening, cancer diagnostics, we're used to, like, really, really bad tests. So like PSA for prostate cancer detection, mammography for breast cancer detection, these things have false positive rates of anywhere from, ah, 50 to 75%.”